In recent years, several options have emerged for treating high‐risk ALL subtypes including targeted agents such as tyrosine kinase inhibitors (imatinib, dasatinib) for Ph+‐ALL and menin inhibitors (e.g., revumenib) for MLLr‐ALL, as well as CD19‐targeting CAR‐T cell therapy and the bispecific T‐cell engager (BiTE) blinatumomab for relapsed/refractory patients.33, 34, 35, 36, 37, 38. Here, CD19 is linked to acute lymphoblastic leukemia.